Why are GLP-1 drugs not recommended for Type 3c diabetes?

There are two main reasons. First, GLP-1 drugs have a known association with pancreatitis, and people with Type 3c diabetes already have a damaged pancreas. Second, GLP-1 drugs work partly by stimulating insulin secretion from beta cells, but in Type 3c the beta cells have already been destroyed or impaired by the original pancreatic disease. The mechanism that makes GLP-1 drugs effective in Type 2 simply does not apply in the same way.

What about Mounjaro or tirzepatide for Type 3c diabetes?

Mounjaro (tirzepatide) combines GLP-1 and GIP receptor agonism. It carries the same pancreatitis risk concerns as other GLP-1 drugs and is not currently recommended for Type 3c diabetes. There is very little clinical evidence for its use in pancreatogenic diabetes specifically.

Are DPP-4 inhibitors safe for Type 3c diabetes?

DPP-4 inhibitors such as sitagliptin (Januvia) are also generally avoided in Type 3c diabetes due to their association with pancreatitis. Like GLP-1 drugs, they work via the incretin pathway, which may aggravate pancreatic inflammation. Insulin is the most commonly used treatment for Type 3c diabetes.

What is the best treatment for Type 3c diabetes?

Most people with Type 3c diabetes are managed with insulin, both long-acting basal insulin and rapid-acting insulin with meals. Alongside insulin, PERT (pancreatic enzyme replacement therapy) is used to manage the exocrine insufficiency that usually accompanies the condition. Careful glucose monitoring, ideally with a CGM and a tracking app, is essential because Type 3c glucose patterns are more unpredictable than Type 1 or Type 2.

GLP-1 Drugs and Type 3c Diabetes: Should You Take Ozempic?

Q: Can you take Ozempic if you have Type 3c diabetes?

Ozempic (semaglutide) is a GLP-1 receptor agonist, and GLP-1 drugs are generally not recommended for Type 3c diabetes. They carry a risk of pancreatitis, which is especially dangerous when your diabetes was caused by pancreatic damage in the first place. Most clinical guidelines recommend insulin and careful glucose monitoring for Type 3c patients instead. Always check with your specialist before starting any new medication.

By Leon Wilkinson, Type 3c patient and developer of GlycoTrace · Updated June 2026

Quick answer

GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro are not recommended for Type 3c diabetes. They carry a risk of pancreatitis, which is particularly dangerous when your diabetes was caused by pancreatic damage. They also work via a mechanism that depends on functioning beta cells, which are already impaired in Type 3c. Most people with Type 3c diabetes are managed with insulin and PERT, not GLP-1 drugs. Always speak to your specialist before changing any medication.

This article is part of our complete guide to Type 3c diabetes, which covers what it is, its causes, diagnosis and day-to-day management.

Why everyone is asking about Ozempic right now

GLP-1 receptor agonists have had an extraordinary few years. Ozempic (semaglutide), Wegovy, Mounjaro (tirzepatide), and Victoza (liraglutide) are everywhere in the news. They were originally developed for Type 2 diabetes, and they have since become widely known for weight loss. If you have diabetes, you have almost certainly been asked about them by a friend or seen them on social media.

If your diabetes was caused by pancreatitis, pancreatic cancer, or another pancreatic condition, that question becomes more complicated. And the answer, for most people with Type 3c diabetes, is that these drugs are not the right choice.

I was diagnosed with Type 3c after pancreatitis. When Ozempic became a household name, I asked my specialist about it. The short answer I got was: not for you. This article explains why, in plain language.

How GLP-1 drugs work

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It tells the pancreas to release insulin, slows digestion, and reduces appetite. GLP-1 receptor agonists mimic this hormone, which is why they lower blood sugar and reduce hunger.

In Type 2 diabetes, the pancreas still has functioning beta cells but the body has become resistant to insulin. GLP-1 drugs nudge those beta cells to work harder. They are effective because the machinery they are stimulating still works.

In Type 3c diabetes, the story is different.

Why Type 3c is not the same as Type 2

Type 3c diabetes happens because the pancreas has been physically damaged. In my case it was pancreatitis. In others it is chronic pancreatitis, pancreatic cancer, surgery to remove part or all of the pancreas, or cystic fibrosis. The common thread is structural damage to the organ itself.

That damage destroys beta cells, which produce insulin. But it also destroys alpha cells, which produce glucagon. This is important because glucagon is what rescues you from a hypo. When your blood sugar drops too low, glucagon tells your liver to release stored glucose. In Type 3c, that rescue system is compromised.

The result is a kind of diabetes that is harder to predict than either Type 1 or Type 2. You can go from normal readings to a dangerous hypo faster than you expect, with less warning. And the body cannot self-correct in the same way.

GLP-1 drugs do not address this. They are built for a different problem.

The pancreatitis risk

Beyond the mechanism mismatch, there is a direct safety concern: GLP-1 drugs have a known association with pancreatitis.

The evidence is debated. Some studies suggest the risk is small. But for someone with a damaged pancreas, even a small additional risk of pancreatitis is a serious concern. Another episode of pancreatitis could worsen existing damage, accelerate insulin deficiency, or cause life-threatening complications.

This is why clinical guidelines, including guidance from Mission:Cure and the Pancreatic Cancer Action Network, specifically state that GLP-1 receptor agonists and DPP-4 inhibitors are not recommended for Type 3c diabetes.

DPP-4 inhibitors, such as sitagliptin (Januvia) and saxagliptin, work via the same incretin pathway and carry the same concerns. These are also generally avoided in Type 3c.

What Type 3c patients actually use

The standard approach for managing Type 3c diabetes is insulin. Most people need both a long-acting basal insulin for background coverage and a rapid-acting insulin with meals.

Getting the meal-time dose right is genuinely difficult. Unlike Type 1 or Type 2, your glucose response after eating depends not just on the carbohydrates in the meal but on how well your enzymes are working that day. If you have exocrine pancreatic insufficiency (EPI), which most Type 3c patients do, the speed and completeness of digestion varies depending on your PERT (pancreatic enzyme replacement therapy) dose, what you ate, and how much fat was in the meal.

This means that glucose tracking in Type 3c is not a simple carb-counting exercise. You are trying to correlate glucose readings with meals, enzyme doses, insulin, and exercise. That is a lot of variables. It is also why a CGM is so useful for Type 3c: the continuous data shows you patterns over days and weeks that finger-prick readings alone would miss.

What I built and why

After my diagnosis, I tried every major diabetes app. Most were built for Type 1 or Type 2. None of them let me log my PERT doses alongside my meals. None of them helped me see the relationship between my Creon dose, my meal, and my glucose reading an hour later.

That is why I built GlycoTrace. It is a free Android app that lets you log glucose, insulin, food, enzyme replacement, and exercise in one place and see how they interact over time. It connects with FreeStyle Libre via LibreLink so you do not need to enter every reading manually if you use a CGM.

It is not a substitute for your diabetes team. But it gives you the data to have better conversations with them.

Track your Type 3c diabetes properly

Log glucose, insulin, meals, and PERT together. Free on Android.

Download on Google Play View demo

What to say to your doctor if you are asked about GLP-1 drugs

Some people with Type 3c are still being managed as Type 2 patients, particularly if they were misdiagnosed before their pancreatic condition was identified. If you have been offered a GLP-1 drug and you know or suspect you have Type 3c, it is worth raising this directly with your GP or specialist.

You might say something like: "I have Type 3c diabetes caused by pancreatitis. My understanding is that GLP-1 drugs carry a pancreatitis risk and that the mechanism is different for pancreatogenic diabetes. Can we discuss whether this is appropriate for me?"

A good specialist will take that seriously. If you do not have a specialist and are still being managed in primary care, ask for a referral to a diabetes team with experience in Type 3c or endocrine-pancreatic conditions.

The Pancreatic Cancer Action Network, Mission:Cure, and Pancreatitis UK all have resources that your GP may not be aware of. It is worth pointing them in that direction.

Common questions

Can you take Ozempic if you have Type 3c diabetes? +

Ozempic (semaglutide) is generally not recommended for Type 3c diabetes. It carries a risk of pancreatitis, which is especially dangerous when your diabetes was caused by pancreatic damage, and it works via a mechanism that depends on functioning beta cells that Type 3c patients no longer have. Always check with your specialist before starting or stopping any medication.

What about Mounjaro or tirzepatide? +

Mounjaro (tirzepatide) combines GLP-1 and GIP receptor agonism and carries the same pancreatitis risk concerns. It is not currently recommended for Type 3c diabetes. There is very limited clinical evidence for its use in pancreatogenic diabetes specifically.

Are DPP-4 inhibitors like Januvia safe for Type 3c? +

DPP-4 inhibitors such as sitagliptin (Januvia) work via the same incretin pathway as GLP-1 drugs and are also generally avoided in Type 3c diabetes due to their association with pancreatitis. Insulin is the most commonly used treatment for Type 3c.

Can metformin be used for Type 3c diabetes? +

Metformin is sometimes used in the early stages of Type 3c diabetes when some insulin-producing capacity remains. Unlike GLP-1 drugs, it does not carry a specific pancreatitis risk. However, most Type 3c patients eventually need insulin as the condition progresses. Metformin may also affect vitamin B12 absorption, which is already a concern for people with exocrine pancreatic insufficiency.

Why is my blood sugar so unpredictable with Type 3c? +

Type 3c diabetes affects both insulin and glucagon production. Without glucagon to act as a buffer when blood sugar falls, hypos can happen quickly and with less warning than in Type 1 or Type 2. Glucose response after meals also varies depending on how well your PERT is working that day and what you ate. A CGM combined with a tracking app that shows you the relationship between meals, enzymes, insulin, and readings can make patterns much clearer over time.